Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma
Release Date: July 19, 2017
Expiration Date: July 19, 2018
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
The addition of new lenalidomide- and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. There are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In this activity, Dr. Harvey will discuss hepatic and renal dysfunction, diabetes, and cardiovascular dysfunction, all of which can impact pharmacy-related decisions such as dose-modification, treatment interruption, or administration of concomitant medications.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Recognize treatment-related adverse events associated with new lenalidomide- and bortezomib-based drug regimens used to treat patients with multiple myeloma
- Identify comorbid conditions and overlapping drug toxicities that warrant pharmacotherapeutic intervention in these patients
- Outline pharmacotherapeutic strategies for managing adverse events associated with these new regimens
Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma – R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Instructions for Participation and Credit
This activity is eligible for credit through July 19, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
R. Donald Harvey III, PharmD, BCOP, FCCP, FHOPA
Department of Pharmacology
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Dr. R. Donald Harvey received his doctor of pharmacy degree from the University of North Carolina (UNC) at Chapel Hill. He completed a hematology/oncology specialty residency at UNC Hospitals and School of Pharmacy, and a pharmacy practice residency at the University of Kentucky Medical Center and College of Pharmacy. Dr. Harvey is an Associate Professor in the Department of Pharmacology and the Department of Hematology and Medical Oncology at Emory University School of Medicine. In addition, he is Director of the Phase I Clinical Trials Section at the Winship Cancer Institute of Emory University in Atlanta, Georgia.
Dr. Harvey holds memberships in the American Society for Clinical Pharmacology and Therapeutics, International Society of Oncology Pharmacy Practitioners, American Society of Hematology, American Society of Clinical Oncology, Hematology-Oncology Pharmacists Association, and the American College of Clinical Pharmacy. He has published more than 60 peer-reviewed articles and has been a principal or co-investigator on more than 80 early phase trials. Dr. Harvey is on the editorial board of the Journal of Oncology Pharmacy Practice and Pharmacotherapy. In addition, he is a manuscript reviewer for the British Journal of Clinical Pharmacology, Clinical Cancer Research, Investigational New Drugs, British Journal of Cancer, Annals of Oncology, Cancer, and the Journal of Clinical Pharmacology, among others. Dr. Harvey’s research focuses on the application of clinical pharmacology principles to improve cancer treatment outcomes.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-144-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. R. Donald Harvey has received honoraria related to formal advisory activities from Aduro Biotech, Bristol-Myers Squibb Company, Huron Pharmaceuticals, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited, as well as consultant fees from Genentech, Inc. He has received grant support related to research activities from AbbVie Inc., Amgen Inc., AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Cleave Biosciences, Calithera BioSciences, Inc., Eli Lilly and Company, Halozyme, Inc., Incyte Corporation, Pfizer Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.